β-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes

Aleksey V Matveyenko, Peter C. Butler

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Type 2 diabetes is characterized by defects in insulin secretion and action and is preceded by impaired fasting glucose (IFG). The islet anatomy in IFG and type 2 diabetes reveals an ∼50 and 65% deficit in β-cell mass, with increased β-cell apoptosis and islet amyloid derived from islet amyloid polypeptide (IAPP). Defects in insulin action include both hepatic and extrahepatic insulin resistance. The relationship between changes in β-cell mass, β-cell function, and insulin action leading to type 2 diabetes are unresolved, in part because it is not possible to measure β-cell mass in vivo, and most available animal models do not recapitulate the islet pathology in type 2 diabetes. We evaluated the HIP rat, a human IAPP transgenic rat model that develops islet pathology comparable to humans with type 2 diabetes, at age 2 months (nondiabetic), 5 months (with IFG), and 10 months (with diabetes) to prospectively examine the relationship between changes in islet morphology versus insulin secretion and action. We report that increased β-cell apoptosis and impaired first-phase insulin secretion precede the development of IFG, which coincides with an ∼50% defect in β-cell mass and onset of hepatic insulin resistance. Diabetes was characterized by ∼70% deficit in β-cell mass, progressive hepatic and extrahepatic insulin resistance, and hyperglucagonemia. We conclude that IAPP-induced β-cell apoptosis causes defects in insulin secretion and β-cell mass that lead first to hepatic insulin resistance and IFG and then to extrahepatic insulin resistance, hyperglucagonemia, and diabetes. We conclude that a specific β-cell defect can recapitulate the metabolic phenotype of type 2 diabetes and note that insulin resistance in type 2 diabetes may at least in part be secondary to β-cell failure.

Original languageEnglish (US)
Pages (from-to)2106-2114
Number of pages9
JournalDiabetes
Volume55
Issue number7
DOIs
StatePublished - Jul 2006
Externally publishedYes

Fingerprint

Islet Amyloid Polypeptide
Transgenic Rats
Type 2 Diabetes Mellitus
Apoptosis
Insulin Resistance
Fasting
Insulin
Glucose
Liver
Pathology
Islets of Langerhans
Amyloid
Anatomy
Animal Models

Keywords

  • IAPP, islet amyloid polypeptide
  • IFG, impaired fasting glucose

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{736ea13ca11946ff88122a43006e313f,
title = "β-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes",
abstract = "Type 2 diabetes is characterized by defects in insulin secretion and action and is preceded by impaired fasting glucose (IFG). The islet anatomy in IFG and type 2 diabetes reveals an ∼50 and 65{\%} deficit in β-cell mass, with increased β-cell apoptosis and islet amyloid derived from islet amyloid polypeptide (IAPP). Defects in insulin action include both hepatic and extrahepatic insulin resistance. The relationship between changes in β-cell mass, β-cell function, and insulin action leading to type 2 diabetes are unresolved, in part because it is not possible to measure β-cell mass in vivo, and most available animal models do not recapitulate the islet pathology in type 2 diabetes. We evaluated the HIP rat, a human IAPP transgenic rat model that develops islet pathology comparable to humans with type 2 diabetes, at age 2 months (nondiabetic), 5 months (with IFG), and 10 months (with diabetes) to prospectively examine the relationship between changes in islet morphology versus insulin secretion and action. We report that increased β-cell apoptosis and impaired first-phase insulin secretion precede the development of IFG, which coincides with an ∼50{\%} defect in β-cell mass and onset of hepatic insulin resistance. Diabetes was characterized by ∼70{\%} deficit in β-cell mass, progressive hepatic and extrahepatic insulin resistance, and hyperglucagonemia. We conclude that IAPP-induced β-cell apoptosis causes defects in insulin secretion and β-cell mass that lead first to hepatic insulin resistance and IFG and then to extrahepatic insulin resistance, hyperglucagonemia, and diabetes. We conclude that a specific β-cell defect can recapitulate the metabolic phenotype of type 2 diabetes and note that insulin resistance in type 2 diabetes may at least in part be secondary to β-cell failure.",
keywords = "IAPP, islet amyloid polypeptide, IFG, impaired fasting glucose",
author = "Matveyenko, {Aleksey V} and Butler, {Peter C.}",
year = "2006",
month = "7",
doi = "10.2337/db05-1672",
language = "English (US)",
volume = "55",
pages = "2106--2114",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "7",

}

TY - JOUR

T1 - β-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes

AU - Matveyenko, Aleksey V

AU - Butler, Peter C.

PY - 2006/7

Y1 - 2006/7

N2 - Type 2 diabetes is characterized by defects in insulin secretion and action and is preceded by impaired fasting glucose (IFG). The islet anatomy in IFG and type 2 diabetes reveals an ∼50 and 65% deficit in β-cell mass, with increased β-cell apoptosis and islet amyloid derived from islet amyloid polypeptide (IAPP). Defects in insulin action include both hepatic and extrahepatic insulin resistance. The relationship between changes in β-cell mass, β-cell function, and insulin action leading to type 2 diabetes are unresolved, in part because it is not possible to measure β-cell mass in vivo, and most available animal models do not recapitulate the islet pathology in type 2 diabetes. We evaluated the HIP rat, a human IAPP transgenic rat model that develops islet pathology comparable to humans with type 2 diabetes, at age 2 months (nondiabetic), 5 months (with IFG), and 10 months (with diabetes) to prospectively examine the relationship between changes in islet morphology versus insulin secretion and action. We report that increased β-cell apoptosis and impaired first-phase insulin secretion precede the development of IFG, which coincides with an ∼50% defect in β-cell mass and onset of hepatic insulin resistance. Diabetes was characterized by ∼70% deficit in β-cell mass, progressive hepatic and extrahepatic insulin resistance, and hyperglucagonemia. We conclude that IAPP-induced β-cell apoptosis causes defects in insulin secretion and β-cell mass that lead first to hepatic insulin resistance and IFG and then to extrahepatic insulin resistance, hyperglucagonemia, and diabetes. We conclude that a specific β-cell defect can recapitulate the metabolic phenotype of type 2 diabetes and note that insulin resistance in type 2 diabetes may at least in part be secondary to β-cell failure.

AB - Type 2 diabetes is characterized by defects in insulin secretion and action and is preceded by impaired fasting glucose (IFG). The islet anatomy in IFG and type 2 diabetes reveals an ∼50 and 65% deficit in β-cell mass, with increased β-cell apoptosis and islet amyloid derived from islet amyloid polypeptide (IAPP). Defects in insulin action include both hepatic and extrahepatic insulin resistance. The relationship between changes in β-cell mass, β-cell function, and insulin action leading to type 2 diabetes are unresolved, in part because it is not possible to measure β-cell mass in vivo, and most available animal models do not recapitulate the islet pathology in type 2 diabetes. We evaluated the HIP rat, a human IAPP transgenic rat model that develops islet pathology comparable to humans with type 2 diabetes, at age 2 months (nondiabetic), 5 months (with IFG), and 10 months (with diabetes) to prospectively examine the relationship between changes in islet morphology versus insulin secretion and action. We report that increased β-cell apoptosis and impaired first-phase insulin secretion precede the development of IFG, which coincides with an ∼50% defect in β-cell mass and onset of hepatic insulin resistance. Diabetes was characterized by ∼70% deficit in β-cell mass, progressive hepatic and extrahepatic insulin resistance, and hyperglucagonemia. We conclude that IAPP-induced β-cell apoptosis causes defects in insulin secretion and β-cell mass that lead first to hepatic insulin resistance and IFG and then to extrahepatic insulin resistance, hyperglucagonemia, and diabetes. We conclude that a specific β-cell defect can recapitulate the metabolic phenotype of type 2 diabetes and note that insulin resistance in type 2 diabetes may at least in part be secondary to β-cell failure.

KW - IAPP, islet amyloid polypeptide

KW - IFG, impaired fasting glucose

UR - http://www.scopus.com/inward/record.url?scp=33747055111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747055111&partnerID=8YFLogxK

U2 - 10.2337/db05-1672

DO - 10.2337/db05-1672

M3 - Article

C2 - 16804082

AN - SCOPUS:33747055111

VL - 55

SP - 2106

EP - 2114

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 7

ER -